Cell-permeable peptide inhibitors of the JNK signal transduction pathway
The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase. Additionally, the present invention provides JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling.
1. A c-Jun amino terminal kinase (JNK) binding peptide, wherein the binding peptide consists of the amino acid sequence of SEQ ID NO:11, wherein all of the amino acids of the binding peptide are in the D isomer form, and wherein the binding peptide is capable of inhibiting JNK kinase activity when the binding peptide is present in a JNK expressing cell.
2. The JNK binding peptide of claim 1 , wherein the JNK binding peptide inhibits the activation of at least one JNK targeted transcription factor when the JNK binding peptide is present in a JNK expressing cell.
3. The JNK binding peptide of claim 2 , wherein the JNK targeted transcription factor is selected from the group consisting of c-Jun, ATF2, and Elk.
4. A pharmaceutical composition comprising the JNK binding peptide of claim 1 , and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is to be administered by an administration route selected from the group consisting of intraperitoneal, nasal, intravenous, oral and patch delivery.
6. A kit comprising the JNK binding peptide according to claim 1 .